

23. (New) A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering to a mammal in need thereof:

- (i) 2 to 12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form;
- (ii) an effective, non-toxic and pharmaceutically acceptable amount of glimepiride; and
- (iii) an effective, non-toxic and pharmaceutically acceptable amount of metformin.

24. (New) A method according to claim 23, which comprises administering 2 to 4 mg, 4 to 8 mg, or 8 to 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Bl 25. (New) A method according to claim 24, which comprises administering 2 to 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

26. (New) A method according to claim 24, which comprises administering 4 to 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

27. (New) A method according to claim 24, which comprises administering 8 to 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

28. (New) A method according to claim 23, which comprises administering 2 mg of said 5-[4-[2-(N-methyl-N-(2-

pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

29. (New) A method according to claim 23, which comprises administering 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

30. (New) A method according to claim 23, which comprises administering 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

31. (New) A method according to claim 23, which comprises administering a unit dosage form of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

32. (New) A method according to claim 23, which comprises administering a unit dosage form comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

33. (New) A method according to claim 32, comprising administering a unit dosage form comprising 1 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

34. (New) A method according to claim 32, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Bl
cont

35. (New) A method according to claim 32, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

36. (New) A method according to claim 32, comprising administering a unit dosage form comprising 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

37. (New) A method according to claim 32, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

B1
cont 1

38. (New) A method according to claim 32, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

39. (New) A method according to claim 23, wherein said unit dosage form is a tablet or a capsule.

40. (New) A method according to claim 23, which comprises co-administering said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, glimepiride, and metformin.

41. (New) A method according to claim 40, which comprises administering a formulation which comprises said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, glimepiride, and metformin.

42. (New) A method according to claim 40, which comprises administration of separate formulations of each of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, glimepiride, and metformin.

43. (New) A method according to claim 23, which comprises sequential administration of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, glimepiride, and metformin.

44. (New) A method according to any one of claims 23-43, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

45. (New) A method according to claim 44, wherein said pharmaceutically acceptable salt is a maleate salt.

46. (New) A method according to any one of claims 23-43, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

47. (New) A method according to any one of claims 23-43, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of said pharmaceutically acceptable salt form.

48. (New) A method according to claim 46, wherein said pharmaceutically acceptable solvate is a hydrate.

49. (New) A method according to claim 47, wherein said pharmaceutically acceptable solvate is a hydrate.

50. (New) A method according to claim 23, which comprises administering a tablet or a capsule comprising 1 to 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, said effective, non-toxic and pharmaceutically

B1
Cont.

acceptable amount of glimepiride, and said effective, non-toxic and pharmaceutically acceptable amount of metformin.

51. (New) A method according to claim 23, which comprises administering a tablet or a capsule comprising a pharmaceutically acceptable salt of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, said effective, non-toxic and pharmaceutically acceptable amount of glimepiride, and said effective, non-toxic and pharmaceutically acceptable amount of metformin.

52. (New) A method according to claim 23, which comprises administering a tablet or a capsule comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, or a tautomer thereof, in a pharmaceutically acceptable form, said effective, non-toxic and pharmaceutically acceptable amount of glimepiride, and said effective, non-toxic and pharmaceutically acceptable amount of metformin.

53. (New) A method for the treatment of Type II diabetes in a mammal, which method comprises administering to a mammal in need thereof:

(i) 2 to 12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form;

(ii) an effective, non-toxic and pharmaceutically acceptable amount of glimepiride; and

(iii) an effective, non-toxic and pharmaceutically acceptable amount of metformin.

54. (New) A method according to claim 53, which comprises administering 2 to 4 mg, 4 to 8 mg, or 8 to 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

55. (New) A method according to claim 54, which comprises administering 2 to 4 mg of said 5-[4-[2-(N-methyl-N-(2-

B1
cont

pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

56. (New) A method according to claim 54, which comprises administering 4 to 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

57. (New) A method according to claim 54, which comprises administering 8 to 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

58. (New) A method according to claim 53, which comprises administering 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

59. (New) A method according to claim 53, which comprises administering 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

60. (New) A method according to claim 53, which comprises administering 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

61. (New) A method according to claim 53, which comprises administering a unit dosage form of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

B1
cont.

62. (New) A method according to claim 53, which comprises administering a unit dosage form comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

63. (New) A method according to claim 62, comprising administering a unit dosage form comprising 1 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

64. (New) A method according to claim 62, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

65. (New) A method according to claim 62, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

66. (New) A method according to claim 62, comprising administering a unit dosage form comprising 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

67. (New) A method according to claim 62, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

68. (New) A method according to claim 62, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-

B1
cont

pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, twice per day.

69. (New) A method according to claim 53, wherein said unit dosage form is a tablet or a capsule.

70. (New) A method according to claim 53, which comprises co-administering said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, glimepiride, and metformin.

71. (New) A method according to claim 70, which comprises administering a formulation which comprises said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, glimepiride, and metformin.

72. (New) A method according to claim 70, which comprises administration of separate formulations of each of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, glimepiride, and metformin.

73. (New) A method according to claim 53, which comprises sequential administration of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, glimepiride, and metformin.

74. (New) A method according to any one of claims 53-73, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

75. (New) A method according to claim 74, wherein said pharmaceutically acceptable salt is a maleate salt.

B1
cont.

76. (New) A method according to any one of claims 53-73, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

77. (New) A method according to any one of claims 53-73, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of said pharmaceutically acceptable salt form.

78. (New) A method according to claim 76, wherein said pharmaceutically acceptable solvate is a hydrate.

79. (New) A method according to claim 77, wherein said pharmaceutically acceptable solvate is a hydrate.

*Bl
cont*

80. (New) A method according to claim 53, which comprises administering a tablet or a capsule comprising 1 to 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, said effective, non-toxic and pharmaceutically acceptable amount of glimepiride, and said effective, non-toxic and pharmaceutically acceptable amount of metformin.

81. (New) A method according to claim 53, which comprises administering a tablet or a capsule comprising a pharmaceutically acceptable salt of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, said effective, non-toxic and pharmaceutically acceptable amount of glimepiride, and said effective, non-toxic and pharmaceutically acceptable amount of metformin.

82. (New) A method according to claim 53, which comprises administering a tablet or a capsule comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, or a tautomer thereof, in a pharmaceutically acceptable form, said effective, non-toxic and pharmaceutically acceptable amount of glimepiride, and said effective, non-toxic and pharmaceutically acceptable amount of metformin.

83. (New) A pharmaceutical composition comprising 1 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, an effective, non-toxic and pharmaceutically acceptable amount of glimepiride, an effective, non-toxic and pharmaceutically acceptable amount of metformin, and a pharmaceutically acceptable carrier therefor.

84. (New) A pharmaceutical composition comprising 1 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form; an effective, non-toxic and pharmaceutically acceptable amount of glimepiride; an effective, non-toxic and pharmaceutically acceptable amount of metformin; and a pharmaceutically acceptable carrier therefor.

B1
cont.

85. (New) A pharmaceutical composition comprising 2 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form; an effective, non-toxic and pharmaceutically acceptable amount of glimepiride; an effective, non-toxic and pharmaceutically acceptable amount of metformin; and a pharmaceutically acceptable carrier therefor.

86. (New) A pharmaceutical composition comprising 4 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form; an effective, non-toxic and pharmaceutically acceptable amount of glimepiride; an effective, non-toxic and pharmaceutically acceptable amount of metformin; and a pharmaceutically acceptable carrier therefor.

87. (New) A pharmaceutical composition comprising 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form; an effective, non-toxic and pharmaceutically acceptable amount of glimepiride; an effective, non-toxic and pharmaceutically acceptable amount of metformin; and a pharmaceutically acceptable carrier therefor.

88. (New) A pharmaceutical composition according to any one of claims 83-87, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

89. (New) A pharmaceutical composition according to claim 88, wherein said pharmaceutically acceptable salt is a maleate salt.

90. (New) A pharmaceutical composition according to any one of claims 83-87, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

91. (New) A pharmaceutical composition according to any one of claims 83-87, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

92. (New) A pharmaceutical composition according to claim 90, wherein said pharmaceutically acceptable solvate is a hydrate.

93. (New) A pharmaceutical composition according to claim 91, wherein said pharmaceutically acceptable solvate is a hydrate.

REMARKS

The claims are 23-93 with claims 23, 53, and 83-87 being independent. Claims 1-22 have been cancelled without prejudice or disclaimer. Support for new claims 23-93 may be found throughout the specification, for example, support for claims 23-30 may be found in original claims 1-12. Support for claims 53-60 may be found in the specification at page 2, lines 2-11 and original claims 1-12. Support for claims 31-38 and 61-68 may be found in the specification at page 6, lines 11-29. Support for claims 39 and 69 may be found in the specification at page 6, lines 13-19. Support for claims 40-43 and 70-73 may be found in the specification at page 2, lines 13-18. Support for claims 44-49 and 74-79 may be found in the specification at page 3, lines 28-35. Support for claims 50-52 and 80-82 may be found in the specification at page 6, lines 13-14 and lines 24-25, and at page 7, lines 9-12. Support for claims 83-87 may